The effect of omega‐3 fatty acids on clinical and paraclinical features of intractable epileptic patients: a triple blind randomized clinical trial
| Autor: | Shahram Arsang-Jang, Mohammad Taheri, Soudeh Ghafouri-Fard, Mir Davood Omrani, Shaghayegh Omrani |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Medicine (miscellaneous) Placebo Gastroenterology law.invention 03 medical and health sciences Epilepsy 0302 clinical medicine Randomized controlled trial Refractory law Refractory seizure Internal medicine medicine lcsh:R5-920 business.industry Research medicine.disease Effective dose (pharmacology) Eicosapentaenoic acid Clinical trial 030104 developmental biology Docosahexaenoic acid Omega 3 030220 oncology & carcinogenesis Molecular Medicine lcsh:Medicine (General) business |
| Zdroj: | Clinical and Translational Medicine Clinical and Translational Medicine, Vol 8, Iss 1, Pp 1-6 (2019) |
| ISSN: | 2001-1326 |
| DOI: | 10.1186/s40169-019-0220-2 |
| Popis: | Long chain omega-3 fatty acids (omega-3 FAs) supplements have been shown to exert beneficial effects in patients with epilepsy through elevation of seizure thresholds and dampening of inflammatory responses. In this triple blind randomized, placebo-controlled parallel group trial of omega-3 FA supplementation, 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA) as well as placebo capsules were administered twice a day in 50 patients with refractory seizure during a 16-week period respectively. Seizure frequency and duration were reduced after completion of the treatment in the supplement group. The supplementation resulted in a significant decrease in TNF-α and IL-6 concentrations. Further studies are needed to compare different omega-3 FA compositions and determine the most effective dose and treatment duration as well as the long term benefits of this supplementation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|